Stockreport

JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline [Yahoo! Finance]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral to an Overweight rating, boosting the price target to $11 from $10. The change follows the solid results of [Read more]